Twenty-six cholecystectomy patients received either an interpleural infusion of bupivacaine (Group B, n = 12) or an intravenous infusion of pethidine (Group P, n = 14) for management of postoperative pain over a three-day period. Patients in Group P experienced a significantly (P < 0.05) greater incidence of total sideeffects (146) than patients in Group B (66). Pain scores (VAS) and responses to a pain questionnaire were similar for both groups; however, within Group B improvement in mean VAS scores at rest with time were more sustained. Similar reductions in FEy;' and FVC from preoperative values occurred for both groups, while for Group P there were significant (P< 0.05) changes in arterial blood gases (increase in PC02, decrease in Po2Y over two days postoperatively. Patients in Group P recorded longer times to passingflatus and unaided mobilisation (P < 0.05), and required a significantly greater number of additional medications (anti-emetics and analgesics) over the postoperative period (41 vs 29, P< 0.05).
pain-relieving effects of interpleural bupivacaine after thoracotomy. 19, 20 The duration of analgesia obtained from a single interpleural bolus of bupivacaine following cholecystectomy is reported to be of the order of four to ten hours. 6 ,8 Hence, as part of an on-going study, an infusion regimen for the interpleural administration ofbupivacaine was developed in an attempt to provide continuous postoperative pain relief over a three-day period. The purpose of the present study was to compare the pharmacodynamics of the interpleural infusion regimen ofbupivacaine with a conventionally used intravenous infusion regimen of pethidine, administered to patients after elective cholecystectomy.
METHODS Patients
With prior approval from the Queen Elizabeth 11 Jubilee Hospital Ethics Committee and written informed consent, 26 patients (7 males and 19 females, aged 19 to 61 years) undergoing elective cholecystectomy were included in the study. Patients with a known history of hypersensitivity to local anaesthetics or pethidine and/or history of pleurisy, chronic liver disease, epilepsy or drug addiction were excluded from this study. The patients were randomly allocated to receive either interpleural bupivacaine (Group B, 12 patients) or intravenous pethidine (Group P, 14 patients).
Operative procedure
All patients received pethidine 100 mg IM prior to surgery. General anaesthesia was induced with thiopentone sodium and maintained with 0.6% to 1.2% enflurane. Suxamethonium and then atracurium were administered for neuromuscular blockade. Muscle relaxation was reversed with atropine and neostigmine at the end of the procedure.
A central venous line was inserted intraoperatively for blood sample withdrawal for bupivacaine concentration measurement.
While still anaesthetised, patients in Group B were turned on their left side and a 16-gauge Tuohy needle was inserted into the sixth intercostal space at the posterior angle of the rib. An epidural catheter was then inserted posterior to the lung using a loss-of-resistance technique. Patients were then extubated and taken to the recovery area. Chest X-rays were performed to confirm the position of the catheter in the pleural space and exclude the possibility of a pneumothorax.
GroupB
Once conscious, each patient received a loading dose of 20 ml of O. 5% bupivacaine (Marcain TU) with adrenaline (1 :200,000) administered into the interpleural catheter as two 10 ml increments given over 60 seconds and separated by a five minute interval. A Terumo TU syringe pump was then used to deliver a continuous interpleural infusion of 8 mlIhour of 0.25% bupivacaine (without adrenaline) for a total time of 72 hours. A second bolus of 20 ml of 0.5% bupivacaine with adrenaline administered in a manner identical to the initial bolus was injected into the catheter at approximately five hours after the start of the infusion.
GroupP
All patients received a bolus dose of pethidine 50 mg followed by an intravenous infusion of 0.5% pethidine, rate-controlled at 30 mg/hour by an infusion pump for 72 hoursY The infusion rate was monitored such that if any patient showed signs of significant respiratory depression (respiratory rate less than twelve breaths per minute) or persistent nausea, the infusion rate was reduced to 20 mg/hour. Metoclopramide (2.4 mg/hour) was added to the infusion regimen of the last five patients because of the high incidence of nausea experienced by previous patients.
All patients in both Groups Band P received supplementary intramuscular pethidine when further analgesia was required. Assessments were conducted preoperatively and twice daily in the mid-morning and mid-afternoon for two days following surgery, and on the morning of the third postoperative day.
Postoperative pain was assessed using a 100 mm horizontal visual analog scale (VAS) with the delimiters 'no pain' and 'worst pain imaginable'. Patients were asked to place a mark on the line to denote the level of their pain at rest and on a separate scale to indicate pain on coughing. Patients were also asked to complete a short pain questionnaire (Table 1) .
Respiratory function parameters, forced expiratory volume in one second (FEV 1) and forced vital capacity (FVC), were measured using a Vitalograph TU Spirometer. Patients were assisted to sit up to perform the assessment. Arterial blood gases were also determined using standard methods of analysis.
Vital signs (heart rate, blood pressure, respiratory rate) were monitored over the three-day period. At the times of the twice-daily assessment patients were requested to report any side-effects, and specifically asked whether they experienced nausea, twitching of the mouth or tongue, dry mouth, involuntary limb movements, drowsiness, dizziness or light-headedness, pruritis, hallucinations or nightmares. Times to first flatus, initiation of solid diet, ambulation about the ward without assistance, and duration of hospital stay were noted. The number of requests for supplementary analgesics and anti-emetics were recorded.
Pain and respiratory data were analysed by the Mann-Whitney U test for unpaired data and the Wilcoxon signed-rank test for paired data. Other parameters were analysed using the Chi-squared statistic. A value of P < 0.05 was considered significant in all cases.
RESULTS
Two patients in Group P were unable to complete the three-day study and withdrew on the first postoperative day because of intractable nausea. Results for Group P include data from the remaining twelve patients only. There was no significant difference between the two groups with respect to age, sex and weight ( Table 2) .
Chest X-rays taken for patients in Group B showed that all catheters were correctly positioned in the pleural space. No significant pneumothorax was detected in any patient.
Patients in Group P experienced a significantly greater number of side-effects (146 incidences) than patients in Group B (66 incidences) (P < 0.05) over the three postoperative days ( Figure 1 ). No significant changes in blood pressure or heart rate were observed. There were three incidences of involuntary lower limb movements reported in each group. The infusion rates of seven patients in Group P were reduced as per protocol by the second postoperative day. Five of these patients withdrew at this time because of drug-induced sideeffects, including respiratory distress (shallow breathing and reduced respiratory rate), nausea, itching and hallucinations.
The mean VAS scores at rest for Groups Band P were 26.2 mm (range 0-59 mm) and 26.4 mm (range 0-63.5 mm) respectively on the morning of the first postoperative day, decreasing to 7.7 mm (range 0-21.5 mm) and 3.9 mm (range 0-11.5 mm) respectively on the third day ( Figure 2 ). There was In Group B, there was a sustained and significant decrease (P< 0.05) in the mean VAS scores at rest at each time of assessment on the second and third postoperative days compared with the score on the first postoperative morning. No such decrease was observed in Group P until the third postoperative morning. There was no significant improvement in the mean VAS scores for pain on coughing between the first postoperative assessment and successive assessments within either group.
Responses to the pain questionnaire supported the VAS results. There was no significant difference in the responses to any of the questions between the two groups. The majority of patients described their pain at rest as 'slight' and pain on coughing as 'moderate' over the first two postoperative days. By the third postoperative morning, a large proportion of the patients had 'no pain' at rest and 'slight pain' on coughing. No patient described the pain at rest as 'severe' at any time of assessment. In addition, the majority of patients in both groups were not kept awake due to pain. Respiratory parameters were calculated as a percentage reduction from preoperative values. For Group B, FEY and FVC dropped by 59% on the morning of the first postoperative day and were still reduced by 42% and 37% respectively on the third day. The corresponding reductions in Group P were 31 % on the first morning and 26% on the third morning for FEY I and 37% and 28% for FYC. There was no significant difference in the mean reduction in FYC between the two groups; however, the mean drop in FEY I on the morning of the first postoperative day was significantly smaller (P < 0.05) in Group P compared with Group B (Figure 3) .
In Group B, mean arterial Peo2 remained essentially unchanged over the first two postoperative days. In comparison, there was a significantly larger rise (P < 0.05) in mean Peo2 in Group P on the first and second postoperative days of + 11.78% and + 8.32%, respectively (Figure 4) . This corresponded to a significant rise in mean bicarbonate concentration [Heo3-] and a significant drop in mean arterial blood pH from preoperative values in Group P on the first postoperative day (P < 0.05). Mean P02 and percentage oxygen saturation were reduced in both groups but to a significantly greater extent (P < 0.05) in Group P on the second postoperative day.
Additional medications were tallied on each postoperative morning and afternoon until the morning of the third day. In those cases where an infusion of metoclopramide was given 
DISCUSSION
In previous studies, we determined the pharmacokinetics of a single bolus interpleural injection of bupivacaine and the steady-state pharmacokinetics of multiple bolus administration over three days postoperatively.22,23 From such data, a regimen consisting of a loading dose followed by a constant interpleural infusion was developed to maintain pain relief over the postoperative period and to provide a theoretical steady-state plasma concentration of 2 mgll. Venous plasma levels of bupivacaine at steadystate obtained in this study were in very close agreement with that predicted (mean 2.10 mg!l±0.54 SD), and are well below the generally accepted toxic concentration of 4 mgll. These results will be discussed in detail elsewhere.
In a pilot study of interpleural infusion patients, the pain relief provided in the first twelve-hour postoperative period was found to be insufficient. This period parallelled a lag in the bupivacaine plasma concentrations prior to reaching steadystate. As a result, an additional interpleural bolus was incorporated into the regimen administered at approximately five hours after initiation of the infusion. This procedure provided more sustained pain relief, but analgesia again diminished towards Anaesthesia and Intensive Care, Vol. 19, No. 4, November, 1991 the end of the first twelve hours as evidenced by the increased requirement for additional analgesics in Group B patients on the morning of the first postoperative day. The introduction of a third bolus into the regimen after approximately ten hours should serve to overcome this problem. As an alternative technique, patient-controlled analgesia (peA) in conjuction with a background infusion, whereby patients could administer interpleural bolus doses on demand, might be a more practical approach to controlling pain over the initial postoperative period.
The bupivacaine interpleural infusion regimen has been shown to provide a satisfactory level of analgesia, comparable with that provided by the pethidine infusion. Patients in the interpleural group experienced marked improvement in the perception of their level of pain over the three-day postoperative period and were able to ambulate unaided more quickly than the pethidine patients, In particular, pain relief was notably improved both at rest and on coughing in the interpleural group on the morning of the second postoperative day (Figure 2 ). As a result, patients were observed to have greater freedom of movement which in some instances may have been taken to excess, perhaps accounting for the small upward turn in the pain scores on the afternoon of the same day.
Pulmonary dysfunction which follows upper abdominal surgery is a multifactorial phenomenon in which pain has been shown to have a significant role. 3 Wound pain may cause splinting of the abdominal muscles thus limiting movement of the thoracic cage and, along with impairment of the diaphragm, diminishes inspiratory and expiratory volumes. I -3 ,24 Our observed reductions in lung volumes are comparable with those reported by others who have examined post-cholecystectomy pulmonary function. 7 -10 A study by Scott and colleagues compared a continuous infusion of interpleural bupivacaine with an infusion of epidural bupivacaine. 10 No difference in the extent of reduction of respiratory volumes (about 50% of preoperative values) was noted between the two patient groups. In another study comparing a single bolus of interpleural bupivacaine with an intramuscular dose of pethidine, Oxorn and Whatley noted lower respiratory volumes following interpleural bupivacaine than with the narcotic regimen. 9 The likely cause of this result was attributed to distribution of bupivacaine from the pleural space across the parietal pleura to block the phrenic nerve, thereby causing further immobility of the diaphragm, 9, 25 In the pethidine group, the raised arterial Pcoz and Hco3-concentrations are indicative of central respiratory depression which is a characteristic of the opioid analgesics. Since reduced alveolar ventilation resulting in hypoxaemia and retardation of regulatory respiratory mechanisms enhances the risk of pulmonary complications, the use of the interpleural technique may be beneficial in high risk patients. 26 Only one other study to date has assessed the postoperative benefits of a continuous interpleural infusion of bupivacaine with an infusion of an opioid analgesic, namely papaveretum. Schroeder and Baker assessed sixteen women who underwent cholecystectomy with regard to postoperative pain, ventilation and other clinical parameters over 72 hours postoperatively. 27 Their findings that pain on movement over the first 48 hours and time to first flatus were less for the interpleural group compared with the narcotic group reflect our observations. However, they also found that ventilatory capacity was depressed to a lesser extent over the first 24 hours with the interpleural infusion. The discrepancy with our results may lie in the type of test performed. We chose to use spirometry which requires maximum effort from the patient and, as a result, closely reflects the effects of pain and therefore analgesia on ventilatory performance. 2 The most important benefits of the interpleural infusion were associated with the lower incidence of side-effects and shorter time to flatus. Although patients in both groups received satisfactory analgesia, it was accompanied by a greater number of recurrent side-effects for patients in the pethidine group and consequently a requirement for more anti-emetic drugs. As a result, there was a high rate of withdrawals in this group of patients. Since gastrointestinal function is not delayed in patients receiving interpleural bupivacaine, they were able to pass flatus sooner. This allows patients to be initiated on free fluids and solid diets earlier.
The above-mentioned advantages to the patients of the interpleural infusion might be expected to be coupled with a reduction in nursing time and workload in maintaining drips, monitoring patient observations and fluid levels and administering injections. Further, a survey of over two hundred patients receiving interpleural bupivacaine by one of the investigators (GAGM -unpublished observation) indicated that these patients are discharged on average a day earlier than patients who receive standard opioid regimens (duration of hospital stay 4.5 vs 5.5 days, respectively). This result was not evident in the present study because protocol stipulations prevented patients leaving before the final assessments were completed.
In conclusion, we have found that an interpleural infusion regimen of bupivacaine provided good postoperative pain relief for 72 hours following cholecystectomy. Pain relief and respiratory capacities were comparable to those produced by an intravenous infusion of pethidine but had the advantage of less respiratory depression, a shorter time to flatus and significantly fewer side-effects than are commonly associated with opioid administration.
